KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Change in Inventory (2020 - 2023)

Ginkgo Bioworks Holdings posted quarterly Change in Inventory of -$694000.0 for Q2 2023, down 16.64% year-on-year from -$832520.2 in Q2 2022, and up 62.59% on a QoQ basis from -$1.9 million in Q1 2023.

Ginkgo Bioworks Holdings (DNA) has 4 years of Change in Inventory data on file, last reported at -$694000.0 in Q2 2023.

  • For the quarter ending Q2 2023, Change in Inventory fell 16.64% year-over-year to -$694000.0; the trailing twelve-month figure through Jun 2023 stood at -$7.5 million (down 238.38% YoY), and the FY2022 full-year result was -$164000.0, down 126.2% from the prior year.
  • Change in Inventory for Q2 2023 stood at -$694000.0, up from -$1.9 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $5.3 million in Q1 2022 and bottomed at -$2.7 million in Q4 2022.
  • The 4-year median for Change in Inventory is -$595000.0 (2022), against an average of -$15454.5.
  • Peak annual rise in Change in Inventory reached 683.41% in 2022, while the deepest fall reached 2276.79% in 2022.
  • A 4-year view of Change in Inventory shows it stood at $1.9 million in 2020, then slumped by 105.84% to -$112000.0 in 2021, then sank by 2276.79% to -$2.7 million in 2022, then surged by 73.93% to -$694000.0 in 2023.
  • The last three Change in Inventory figures came in at -$694000.0 (Q2 2023), -$1.9 million (Q1 2023), and -$2.7 million (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Inventory (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 665.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 97.70 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -26.60 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 3.32 Mn
10 Ginkgo Bioworks Holdings 542.03 Mn 542.03 Mn 16.38 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 -694,000.00
Jun 30, 2023 -694,000.00
Mar 31, 2023 -1.86 Mn
Mar 31, 2023 -1.86 Mn
Dec 31, 2022 -2.66 Mn
Dec 31, 2022 -2.66 Mn
Sep 30, 2022 -2.24 Mn
Sep 30, 2022 -2.24 Mn
Jun 30, 2022 -595,000.00
Jun 30, 2022 -595,000.00
Mar 31, 2022 5.34 Mn
Mar 31, 2022 5.34 Mn
Dec 31, 2021 -112,000.00
Dec 31, 2021 -112,000.00
Sep 30, 2021 758,000.00
Sep 30, 2021 758,000.00
Jun 30, 2021 -701,000.00
Jun 30, 2021 -701,000.00
Mar 31, 2021 681,000.00
Mar 31, 2021 681,000.00
Dec 31, 2020 1.92 Mn
Dec 31, 2020 1.92 Mn